MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Axsome Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

106.25 0.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

105.13

Max

106.25

Galvenie mērījumi

By Trading Economics

Ienākumi

-10M

-75M

Pārdošana

14M

119M

EPS

-1.54

Peļņas marža

-63.075

Darbinieki

683

EBITDA

-10M

-71M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+66.84% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.1B

5.1B

Iepriekšējā atvēršanas cena

105.3

Iepriekšējā slēgšanas cena

106.25

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Axsome Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 25. apr. 17:01 UTC

Peļņas
Galvenie tirgus virzītāji

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

2025. g. 25. apr. 16:10 UTC

Peļņas
Galvenie tirgus virzītāji

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

2025. g. 26. apr. 18:14 UTC

Peļņas

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

2025. g. 26. apr. 15:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

2025. g. 26. apr. 08:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 25. apr. 21:24 UTC

Top Ziņas

Cargo Shipments From China to the U.S. Dwindle -- WSJ

2025. g. 25. apr. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 25. apr. 20:45 UTC

Top Ziņas

Stocks Claw Back Most of April's Tariff Losses -- WSJ

2025. g. 25. apr. 20:39 UTC

Peļņas

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

2025. g. 25. apr. 20:37 UTC

Top Ziņas

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

2025. g. 25. apr. 20:19 UTC

Top Ziņas

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

2025. g. 25. apr. 20:15 UTC

Peļņas

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

2025. g. 25. apr. 19:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

2025. g. 25. apr. 19:18 UTC

Tirgus saruna

Oil Futures End Choppy Week With Losses -- Market Talk

2025. g. 25. apr. 18:47 UTC

Tirgus saruna

Gold Extends Pullback to Close Week -- Market Talk

2025. g. 25. apr. 18:39 UTC

Top Ziņas

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

2025. g. 25. apr. 18:34 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

2025. g. 25. apr. 18:32 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 25. apr. 18:32 UTC

Tirgus saruna
Peļņas

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

2025. g. 25. apr. 18:08 UTC

Peļņas

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

2025. g. 25. apr. 17:55 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

2025. g. 25. apr. 17:40 UTC

Top Ziņas

Consumers Continue to Sour on the Economy -- 4th Update

2025. g. 25. apr. 17:38 UTC

Peļņas

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

2025. g. 25. apr. 17:07 UTC

Tirgus saruna

Oil Futures Turn Higher in Quiet Trade -- Market Talk

2025. g. 25. apr. 16:54 UTC

Tirgus saruna
Peļņas

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

2025. g. 25. apr. 16:46 UTC

Peļņas

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

2025. g. 25. apr. 16:20 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 25. apr. 16:12 UTC

Top Ziņas

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

2025. g. 25. apr. 16:03 UTC

Peļņas

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025. g. 25. apr. 15:52 UTC

Tirgus saruna

Grains Mixed on Low Volume Trade -- Market Talk

Salīdzinājums

Cenas izmaiņa

Axsome Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

66.84% augšup

Prognoze 12 mēnešiem

Vidējais 175.87 USD  66.84%

Augstākais 216 USD

Zemākais 133 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Axsome Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

18

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

104.22 / N/AAtbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Strong Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.